This clinical trial focuses on preventing the recurrence of External Genital Warts (EGW), a condition caused by Human Papillomavirus (HPV). The study aims to determine if vaccination with Gardasil or Gardasil 9 can reduce the rate of wart recurrence in patients who have been successfully treated for their initial wart infection.

The study compares the effectiveness of HPV vaccines against a placebo (saline solution) in preventing warts from coming back. The vaccines contain proteins that resemble parts of different HPV virus types. These proteins are made in a laboratory using special yeast cells and are combined into a liquid that can be injected into a muscle.

Treatment involves receiving three injections over a 6-month period, with each injection containing 0.5 milliliters of either the vaccine or placebo. Patients will be monitored for 12 months after their first injection to check if the warts return and to observe any reactions to the treatment. The total duration of participation in the study is one year.